Materiały źródłowe

• #1 Paraneoplastic syndromes of the nervous system – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/diagnosis-treatment/drc-20355691

  Treatment of paraneoplastic syndromes of the nervous system involves treating the cancer. Sometimes treatment also involves suppressing the immune response that’s causing your symptoms. Your treatment depends on the type of paraneoplastic syndrome you have. It may include the following options. […] In addition to cancer treatments, such as chemotherapy, your healthcare professional may prescribe one or more medicines. These medicines can help stop your immune system from damaging your nervous system: […] Corticosteroids, such as prednisone, inhibit inflammation. These medicines can have serious long-term side effects. Corticosteroids may lead to type 2 diabetes, high blood pressure, high cholesterol and weakened bones, known as osteoporosis. The medicine also can cause other conditions.

• #2 Paraneoplastic syndromes of the nervous system – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/symptoms-causes/syc-20355687

  Paraneoplastic syndromes of the nervous system can affect muscle movement, coordination, sensory perception, memory, thinking skills or even sleep. […] Sometimes the injury to the nervous system can be reversed with therapy directed toward the cancer and the immune system. But sometimes paraneoplastic syndromes can result in permanent damage to the nervous system. […] Treating the cancer and other therapies may prevent further damage and improve symptoms and quality of life. […] But if you have any symptoms suggesting a paraneoplastic syndrome, see your healthcare professional as soon as possible. Early diagnosis and appropriate care are important for treating the cancer and preventing further damage of the nervous system.

• #3 Paraneoplastic Syndromes | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/26633

  Management of a patient with paraneoplastic syndrome is based on the type, severity, and location of the paraneoplastic syndrome. If occult malignancy is diagnosed, then the first step is to treat the underlying malignancy with chemotherapy, radiation, or surgery when possible. A paraneoplastic syndrome is an auto-immune process; patients may benefit from immunosuppression with high-dose corticosteroids, intravenous immunoglobulins, plasma exchange, or plasmapheresis. […] Tumor-related hypercalcemia: Patients with calcium levels14mg/dl (3.5mmol/L) require aggressive treatment with intravenous fluids. If they develop fluid overload, consider intravenous Lasix. If calcium is still high, consider giving intravenous calcitonin with Bisphosphonates (Subcutaneous Zolendronic acid or intravenous pamidronate). Calcitonin will decrease the calcium levels acutely, but there is a risk of developing tachyphylaxis. Bisphosphonates will take 1 to 2 days to decrease calcium levels.

• #4 Diagnosis and Management of Paraneoplastic Neurologic Disorders

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3844017/

  For all PND, prompt identification and treatment of the tumor is important as this has been found in several series to be the main factor associated with stabilization or improvement of the PND. […] Treatments directed at the PND are primarily immunosuppressive and immunomodulatory. Initial therapies often include corticosteroids, plasma exchange, IVIg and/or rituximab. […] There are few trials examining optimal treatment strategies for PND. Most treatments are empirically based on data from other autoimmune diseases and reports from cases series and cohort studies. […] Corticosteroids are commonly and empirically used in conjunction with other treatments such as IVIg or plasma exchange. […] Cyclophosphamide is a broad immunosuppressive agent that decreases both humoral and cellular immunity.

• #5 Diagnosis and Management of Paraneoplastic Neurologic Disorders

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3844017/

  Paraneoplastic neurologic disorders (PND) are a heterogeneous group of immune-mediated neurological disorders associated with systemic cancers. When a PND is diagnosed prompt identification and treatment of the associated tumor is important as PND stabilization and in some cases improvement have been reported after tumor treatment. […] Treatments aimed at the PND are mostly immunosuppressive and include corticosteroids, plasma exchange and intravenous immunoglobulins (IVIg). Immunosuppressive chemotherapeutics and B-cell targeting drugs such as rituximab may also be useful. […] For treatment purposes the immune-mediated PND can be divided into those in which the antibodies are pathogenic and those in which cytotoxic T-cells are the main effectors of the neurologic dysfunction. […] For those PND that are likely T-cell mediated (e.g, anti-Hu associated encephalomyelitis), immunosuppression or immunomodulation is recommended but responses are less likely as irreversible neuronal damage appears to occur rapidly and early.

• #6 Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes

  https://www.mdpi.com/2073-4468/12/3/50

  First-line immunotherapy typically consists of corticosteroids, intravenous immunoglobulin (IVIG) and/or plasmapheresis. […] Unfortunately, PNSs caused by antibodies directed against intracellular antigens and mediated by T cells tend to be poorly responsive to treatment. […] For these patients, in addition to treating the primary malignancy, early and aggressive immunomodulatory and immunosuppressive treatment with corticosteroids and IVIG provide the best chance of neurologic recovery, likely because neuronal damage is not yet complete. […] More aggressive cytotoxic (e.g., cyclophosphamide, an alkylating agent that predominantly depletes T cells) or immunosuppressive (e.g., tacrolimus and cyclosporine) agents can also be trialed. […] Unfortunately, PNSs caused by antibodies directed against intracellular antigens and mediated by T cells tend to be poorly responsive to treatment.

• #7 Paraneoplastic syndromes of the nervous system – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/diagnosis-treatment/drc-20355691

  Treatment of paraneoplastic syndromes of the nervous system involves treating the cancer. Sometimes treatment also involves suppressing the immune response that’s causing your symptoms. Your treatment depends on the type of paraneoplastic syndrome you have. It may include the following options. […] In addition to cancer treatments, such as chemotherapy, your healthcare professional may prescribe one or more medicines. These medicines can help stop your immune system from damaging your nervous system: […] Corticosteroids, such as prednisone, inhibit inflammation. These medicines can have serious long-term side effects. Corticosteroids may lead to type 2 diabetes, high blood pressure, high cholesterol and weakened bones, known as osteoporosis. The medicine also can cause other conditions.

• #8 Paraneoplastic Syndromes: Symptoms, Types & Treatment

  https://my.clevelandclinic.org/health/diseases/17938-paraneoplastic-syndromes

  Your healthcare provider will treat the underlying cancer thats causing your symptoms. Theyll also work to manage your symptoms to decrease any damage to your bodys organs or systems. […] Therapies used to manage paraneoplastic syndromes include: […] Corticosteroids: Medications, such as cortisone or prednisone, that reduce inflammation (swelling). […] Immunosuppression: Drugs that decrease your bodys immune response. The drug therapies your provider prescribes will be tailored to your paraneoplastic syndrome. […] Intravenous immunoglobulin: Treatment that destroys the harmful antibodies causing the syndrome. During the procedure, your provider gives you a shot of healthy antibodies that destroy the harmful ones. […] Plasmapheresis: A procedure that decreases the number of antibodies by removing plasma (liquid) from your blood. The plasma contains the antibodies that damage healthy tissue. […] Physical and speech therapy: Muscle exercises that can help improve functions like speech and movement. You may need this therapy if you have a neurological paraneoplastic syndrome.

• #9 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Treatment of paraneoplastic syndromes of the nervous system involves treating the cancer. Sometimes treatment also involves suppressing the immune response that’s causing your symptoms. Your treatment depends on the type of paraneoplastic syndrome you have. It may include the following options. […] In addition to cancer treatments, such as chemotherapy, your healthcare professional may prescribe one or more medicines. These medicines can help stop your immune system from damaging your nervous system: […] Corticosteroids, such as prednisone, inhibit inflammation. These medicines can have serious long-term side effects. Corticosteroids may lead to type 2 diabetes, high blood pressure, high cholesterol and weakened bones, known as osteoporosis. The medicine also can cause other conditions.

• #10 Paraneoplastic syndromes of the nervous system

  https://www.mymlc.com/health-information/diseases-and-conditions/p/paraneoplastic-syndromes-of-the-nervous-system/

  Treatment of neurological paraneoplastic syndromes involves treating the cancer and, in some cases, suppressing the immune response that’s causing your signs and symptoms. Your treatment will depend on the specific type of paraneoplastic syndrome you have, but it may include the following options. […] In addition to drugs, such as chemotherapy, to combat your cancer, your doctor may prescribe one or more of the following drugs to stop your immune system from attacking your nervous system: […] Corticosteroids, such as prednisone, inhibit inflammation. Serious long-term side effects include weakening of the bones (osteoporosis), type 2 diabetes, high blood pressure, high cholesterol and others. […] Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. Drugs may include azathioprine (Imuran, Azasan) and cyclophosphamide.

• #11 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Intravenous immunoglobulin (IVIg). Immunoglobulin contains healthy antibodies from blood donors. High doses of immunoglobulin speed up the destruction of the damaging antibodies in your blood. […] If you have a paraneoplastic neurologic syndrome, it’s generally recommended that you don’t use certain cancer medicines called immune checkpoint inhibitors. These treatments activate the immune system to fight cancer. While this can help destroy the cancer, it also can lead to worsening of the immune attack on the nervous system. […] Other therapies may be helpful if a paraneoplastic syndrome has caused disability: Physical therapy. Specific exercises may help you regain some lost muscle function. […] Speech therapy. A speech therapist can help you relearn the necessary muscle control if you are having trouble speaking or swallowing.

• #12 Diagnosis and Management of Paraneoplastic Neurologic Disorders

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3844017/

  Despite use over many years, the mechanisms by which IVIg modulates immune function are not well understood but it appears to decrease T-cell proliferation, suppress B-cell differentiation and decrease levels of pro-inflammatory cytokines. […] Rituximab is mostly reserved for those disorders in which antibodies are pathogenic (e.g, anti-NMDA receptor encephalitis) as antibody depleting strategies such as plasma exchange and IVIg are far more effective in depleting peripheral but not central nervous system antibody titers. […] Plasma exchange reduces serum levels of antibodies and is therefore useful for those PND of the peripheral nervous system directly mediated by antibodies. […] Patients with brainstem or cerebellar dysfunction may require wheelchairs and feeding tube placement. Seizures associated with encephalitis often respond to conventional anti-epileptics. […] Treatment of the tumor and corticosteroids, adrenocorticotropic hormone, plasma exchange, IVIg, or rituximab, result in improvement in one half to two thirds of patients although many children have residual cognitive and behavioral deficits.

• #13 Diagnosis and Management of Paraneoplastic Neurologic Disorders

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3844017/

  Despite use over many years, the mechanisms by which IVIg modulates immune function are not well understood but it appears to decrease T-cell proliferation, suppress B-cell differentiation and decrease levels of pro-inflammatory cytokines. […] Rituximab is mostly reserved for those disorders in which antibodies are pathogenic (e.g, anti-NMDA receptor encephalitis) as antibody depleting strategies such as plasma exchange and IVIg are far more effective in depleting peripheral but not central nervous system antibody titers. […] Plasma exchange reduces serum levels of antibodies and is therefore useful for those PND of the peripheral nervous system directly mediated by antibodies. […] Patients with brainstem or cerebellar dysfunction may require wheelchairs and feeding tube placement. Seizures associated with encephalitis often respond to conventional anti-epileptics. […] Treatment of the tumor and corticosteroids, adrenocorticotropic hormone, plasma exchange, IVIg, or rituximab, result in improvement in one half to two thirds of patients although many children have residual cognitive and behavioral deficits.

• #14 Paraneoplastic Syndromes: Symptoms, Types & Treatment

  https://my.clevelandclinic.org/health/diseases/17938-paraneoplastic-syndromes

  Your healthcare provider will treat the underlying cancer thats causing your symptoms. Theyll also work to manage your symptoms to decrease any damage to your bodys organs or systems. […] Therapies used to manage paraneoplastic syndromes include: […] Corticosteroids: Medications, such as cortisone or prednisone, that reduce inflammation (swelling). […] Immunosuppression: Drugs that decrease your bodys immune response. The drug therapies your provider prescribes will be tailored to your paraneoplastic syndrome. […] Intravenous immunoglobulin: Treatment that destroys the harmful antibodies causing the syndrome. During the procedure, your provider gives you a shot of healthy antibodies that destroy the harmful ones. […] Plasmapheresis: A procedure that decreases the number of antibodies by removing plasma (liquid) from your blood. The plasma contains the antibodies that damage healthy tissue. […] Physical and speech therapy: Muscle exercises that can help improve functions like speech and movement. You may need this therapy if you have a neurological paraneoplastic syndrome.

• #15 Paraneoplastic syndromes of the nervous system – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/paraneoplastic-syndromes/diagnosis-treatment/drc-20355691

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Other treatments that may improve symptoms include: […] Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #16 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #17 Diagnosis and Management of Paraneoplastic Neurologic Disorders

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3844017/

  Despite use over many years, the mechanisms by which IVIg modulates immune function are not well understood but it appears to decrease T-cell proliferation, suppress B-cell differentiation and decrease levels of pro-inflammatory cytokines. […] Rituximab is mostly reserved for those disorders in which antibodies are pathogenic (e.g, anti-NMDA receptor encephalitis) as antibody depleting strategies such as plasma exchange and IVIg are far more effective in depleting peripheral but not central nervous system antibody titers. […] Plasma exchange reduces serum levels of antibodies and is therefore useful for those PND of the peripheral nervous system directly mediated by antibodies. […] Patients with brainstem or cerebellar dysfunction may require wheelchairs and feeding tube placement. Seizures associated with encephalitis often respond to conventional anti-epileptics. […] Treatment of the tumor and corticosteroids, adrenocorticotropic hormone, plasma exchange, IVIg, or rituximab, result in improvement in one half to two thirds of patients although many children have residual cognitive and behavioral deficits.

• #18 Paraneoplastic Syndromes

  https://www.brainfacts.org/diseases-and-disorders/neurological-disorders-az/diseases-a-to-z-from-ninds/paraneoplastic-syndromes

  When present, the tumor and cancer are treated first, followed by efforts to decrease the autoimmune response — either through steroids such as cortisone or prednisone, high-dose intravenous immunoglobulin, or irradiation. […] Plasmapheresis, a process that cleanses antibodies from the blood, may ease symptoms in people with paraneoplastic disorders that affect the peripheral nervous system. […] Speech and physical therapy may help individuals regain some functions.

• #19 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #20 Diagnosis and Management of Paraneoplastic Neurologic Disorders

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3844017/

  Despite use over many years, the mechanisms by which IVIg modulates immune function are not well understood but it appears to decrease T-cell proliferation, suppress B-cell differentiation and decrease levels of pro-inflammatory cytokines. […] Rituximab is mostly reserved for those disorders in which antibodies are pathogenic (e.g, anti-NMDA receptor encephalitis) as antibody depleting strategies such as plasma exchange and IVIg are far more effective in depleting peripheral but not central nervous system antibody titers. […] Plasma exchange reduces serum levels of antibodies and is therefore useful for those PND of the peripheral nervous system directly mediated by antibodies. […] Patients with brainstem or cerebellar dysfunction may require wheelchairs and feeding tube placement. Seizures associated with encephalitis often respond to conventional anti-epileptics. […] Treatment of the tumor and corticosteroids, adrenocorticotropic hormone, plasma exchange, IVIg, or rituximab, result in improvement in one half to two thirds of patients although many children have residual cognitive and behavioral deficits.

• #21 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #22 Diagnosis and Management of Paraneoplastic Neurologic Disorders

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3844017/

  For all PND, prompt identification and treatment of the tumor is important as this has been found in several series to be the main factor associated with stabilization or improvement of the PND. […] Treatments directed at the PND are primarily immunosuppressive and immunomodulatory. Initial therapies often include corticosteroids, plasma exchange, IVIg and/or rituximab. […] There are few trials examining optimal treatment strategies for PND. Most treatments are empirically based on data from other autoimmune diseases and reports from cases series and cohort studies. […] Corticosteroids are commonly and empirically used in conjunction with other treatments such as IVIg or plasma exchange. […] Cyclophosphamide is a broad immunosuppressive agent that decreases both humoral and cellular immunity.

• #23 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #24 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #25 Paraneoplastic syndromes of the nervous system

  https://www.mymlc.com/health-information/diseases-and-conditions/p/paraneoplastic-syndromes-of-the-nervous-system/

  Treatment of neurological paraneoplastic syndromes involves treating the cancer and, in some cases, suppressing the immune response that’s causing your signs and symptoms. Your treatment will depend on the specific type of paraneoplastic syndrome you have, but it may include the following options. […] In addition to drugs, such as chemotherapy, to combat your cancer, your doctor may prescribe one or more of the following drugs to stop your immune system from attacking your nervous system: […] Corticosteroids, such as prednisone, inhibit inflammation. Serious long-term side effects include weakening of the bones (osteoporosis), type 2 diabetes, high blood pressure, high cholesterol and others. […] Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. Drugs may include azathioprine (Imuran, Azasan) and cyclophosphamide.

• #26 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #27 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #28 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #29 Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes

  https://www.mdpi.com/2073-4468/12/3/50

  First-line immunotherapy typically consists of corticosteroids, intravenous immunoglobulin (IVIG) and/or plasmapheresis. […] Unfortunately, PNSs caused by antibodies directed against intracellular antigens and mediated by T cells tend to be poorly responsive to treatment. […] For these patients, in addition to treating the primary malignancy, early and aggressive immunomodulatory and immunosuppressive treatment with corticosteroids and IVIG provide the best chance of neurologic recovery, likely because neuronal damage is not yet complete. […] More aggressive cytotoxic (e.g., cyclophosphamide, an alkylating agent that predominantly depletes T cells) or immunosuppressive (e.g., tacrolimus and cyclosporine) agents can also be trialed. […] Unfortunately, PNSs caused by antibodies directed against intracellular antigens and mediated by T cells tend to be poorly responsive to treatment.

• #30 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #31 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Immunosuppressants slow the production of disease-fighting white blood cells. Side effects include an increased risk of infections. These medicines include azathioprine (Imuran, Azasan), mycophenolate (CellCept), rituximab (Rituxan, Riabni, others) and cyclophosphamide (Cytoxan). They also include methotrexate (Trexall, Xatmep, others), cyclosporine (Gengraf, Neoral, others), and tacrolimus (Astagraf XL, Envarsus XR, others). Newer medicines include eculizumab (Soliris), ravulizumab (Ultomiris) and efgartigimod (Vyvgart). […] Depending on the type of paraneoplastic syndrome and symptoms, other medicines may include: Anti-seizure medicines, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Other treatments that may improve symptoms include: Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a blood cell separator. The plasma, which contains the antibodies causing symptoms, is discarded and replaced with other fluids. Your red and white blood cells, along with your platelets, are returned to your body.

• #32 Diagnosis and Management of Paraneoplastic Neurologic Disorders

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3844017/

  Despite use over many years, the mechanisms by which IVIg modulates immune function are not well understood but it appears to decrease T-cell proliferation, suppress B-cell differentiation and decrease levels of pro-inflammatory cytokines. […] Rituximab is mostly reserved for those disorders in which antibodies are pathogenic (e.g, anti-NMDA receptor encephalitis) as antibody depleting strategies such as plasma exchange and IVIg are far more effective in depleting peripheral but not central nervous system antibody titers. […] Plasma exchange reduces serum levels of antibodies and is therefore useful for those PND of the peripheral nervous system directly mediated by antibodies. […] Patients with brainstem or cerebellar dysfunction may require wheelchairs and feeding tube placement. Seizures associated with encephalitis often respond to conventional anti-epileptics. […] Treatment of the tumor and corticosteroids, adrenocorticotropic hormone, plasma exchange, IVIg, or rituximab, result in improvement in one half to two thirds of patients although many children have residual cognitive and behavioral deficits.

• #33 Paraneoplastic syndromes of the nervous system

  https://www.mymlc.com/health-information/diseases-and-conditions/p/paraneoplastic-syndromes-of-the-nervous-system/

  Depending on the type of neurological syndrome and symptoms, other medications may include: […] Anti-seizure medications, which may help control seizures associated with syndromes that cause electrical instability in the brain. […] Medications to enhance nerve-to-muscle transmission, which may improve symptoms of syndromes affecting muscle function. Some drugs enhance the release of a chemical messenger that transmits a signal from nerve cells to muscles. Other drugs, such as pyridostigmine (Mestinon, Regonol), prevent the breakdown of these chemical messengers. […] Other treatments that may improve symptoms include: […] Plasmapheresis. This process separates the fluid part of the blood, called plasma, from your blood cells with a device known as a cell separator. Technicians return your red and white blood cells, along with your platelets, to your body, while discarding the plasma, which contains unwanted antibodies, and replacing it with other fluids.

• #34 Paraneoplastic Syndromes of the Nervous System | LEMS Aware HCPLEMS Aware logoLEMS Aware on LinkedInLEMS Aware on TwitterLEMS Aware on FacebookCatalyst Logo

  https://www.lemsawarehcp.com/paraneoplastic-syndromes/

  Paraneoplastic syndromes of the nervous system are a heterogeneous group of neurological disorders caused by the immune response to an underlying tumor—specifically, against the onconeural antigen expressed by both the tumor and the nervous system. These syndromes are not caused by cancer metastasis. LEMS is considered a classic example of this syndrome. […] Timely diagnosis, prompt symptomatic neurological treatment, and treatment of the underlying malignancy are essential components of management of these cases. […] Among patients who received symptomatic treatment with 3,4-DAP or pyridostigmine, 88% reported improvement in symptoms due to 3,4-DAP vs only 67% who reported improvement due to pyridostigmine (N=150). […] Patients treated with symptomatic therapy appeared to improve sooner after diagnosis vs those treated with immunosuppressive drugs. […] Amifampridine. Symptomatic treatment of LEMS is recommended in addition to anticancer therapy for patients with cancer-associated LEMS. While steroids, IVIG, and pyridostigmine have all been used in limited capacity for the treatment of LEMS, only amifampridine is approved and recommended for LEMS.

• #35 Paraneoplastic Syndromes of the Nervous System | LEMS Aware HCPLEMS Aware logoLEMS Aware on LinkedInLEMS Aware on TwitterLEMS Aware on FacebookCatalyst Logo

  https://www.lemsawarehcp.com/paraneoplastic-syndromes/

  Paraneoplastic syndromes of the nervous system are a heterogeneous group of neurological disorders caused by the immune response to an underlying tumor—specifically, against the onconeural antigen expressed by both the tumor and the nervous system. These syndromes are not caused by cancer metastasis. LEMS is considered a classic example of this syndrome. […] Timely diagnosis, prompt symptomatic neurological treatment, and treatment of the underlying malignancy are essential components of management of these cases. […] Among patients who received symptomatic treatment with 3,4-DAP or pyridostigmine, 88% reported improvement in symptoms due to 3,4-DAP vs only 67% who reported improvement due to pyridostigmine (N=150). […] Patients treated with symptomatic therapy appeared to improve sooner after diagnosis vs those treated with immunosuppressive drugs. […] Amifampridine. Symptomatic treatment of LEMS is recommended in addition to anticancer therapy for patients with cancer-associated LEMS. While steroids, IVIG, and pyridostigmine have all been used in limited capacity for the treatment of LEMS, only amifampridine is approved and recommended for LEMS.

• #36 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Intravenous immunoglobulin (IVIg). Immunoglobulin contains healthy antibodies from blood donors. High doses of immunoglobulin speed up the destruction of the damaging antibodies in your blood. […] If you have a paraneoplastic neurologic syndrome, it’s generally recommended that you don’t use certain cancer medicines called immune checkpoint inhibitors. These treatments activate the immune system to fight cancer. While this can help destroy the cancer, it also can lead to worsening of the immune attack on the nervous system. […] Other therapies may be helpful if a paraneoplastic syndrome has caused disability: Physical therapy. Specific exercises may help you regain some lost muscle function. […] Speech therapy. A speech therapist can help you relearn the necessary muscle control if you are having trouble speaking or swallowing.

• #37 Paraneoplastic syndromes of the nervous system

  https://www.mymlc.com/health-information/diseases-and-conditions/p/paraneoplastic-syndromes-of-the-nervous-system/

  Intravenous immunoglobulin (IVIg). Immunoglobulin contains healthy antibodies from blood donors. High doses of immunoglobulin speed up the destruction of the damaging antibodies in your blood. […] Other therapies may be helpful if a paraneoplastic syndrome has caused significant disability: […] Physical therapy. Specific exercises may help you regain some muscle function that has been damaged. […] Speech therapy. If you are having trouble speaking or swallowing, a speech therapist can help you relearn the necessary muscle control.

• #38 Paraneoplastic syndromes of the nervous system – Humanitas.net

  https://www.humanitas.net/diseases/paraneoplastic-syndromes-of-the-nervous-system/

  Treatment for paraneoplastic syndromes typically involves treating the cancer itself, improving symptoms and physical therapy if necessary. […] Treatment of neurological paraneoplastic syndromes involves treating the cancer and improving symptoms that cause pain and discomfort. Treatment options can include: […] Other medical procedures may include: […] Other types of therapies that may be helpful if a paraneoplastic syndrome has caused significant disability include: […] Physical therapy: A rehabilitation program that uses specific exercises to help regain muscular function and coordination. […] Speech therapy: A clinical program aimed to help improve speech skills as well as oral motor skills to relearn muscle control.

• #39 What Are Paraneoplastic Syndromes?

  https://www.healthline.com/health/cancer/paraneoplastic-syndromes

  The first course of action is to treat cancer itself. Other treatment options may involve: […] Corticosteroids. These medications may help ease swelling and reduce your body’s overactive immune system response. […] Immunosuppressive drugs. These medications help to reduce your body’s autoimmune response as well. […] Intravenous immunoglobulins (IVIG). These medications are given by an IV (into your vein), and they help limit the number of antibodies in your blood. […] Plasmapheresis. This is a process that filters out antibodies from the plasma, or liquid part, of your blood. […] Physical and speech therapy. These therapies may help improve speech, swallowing, and movement helping you function better longer. […] Treatments aim to relieve symptoms, reduce any swelling, and suppress the body’s immune response to these syndromes.

• #40 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Intravenous immunoglobulin (IVIg). Immunoglobulin contains healthy antibodies from blood donors. High doses of immunoglobulin speed up the destruction of the damaging antibodies in your blood. […] If you have a paraneoplastic neurologic syndrome, it’s generally recommended that you don’t use certain cancer medicines called immune checkpoint inhibitors. These treatments activate the immune system to fight cancer. While this can help destroy the cancer, it also can lead to worsening of the immune attack on the nervous system. […] Other therapies may be helpful if a paraneoplastic syndrome has caused disability: Physical therapy. Specific exercises may help you regain some lost muscle function. […] Speech therapy. A speech therapist can help you relearn the necessary muscle control if you are having trouble speaking or swallowing.

• #41 Paraneoplastic syndromes of the nervous system

  https://www.mymlc.com/health-information/diseases-and-conditions/p/paraneoplastic-syndromes-of-the-nervous-system/

  Intravenous immunoglobulin (IVIg). Immunoglobulin contains healthy antibodies from blood donors. High doses of immunoglobulin speed up the destruction of the damaging antibodies in your blood. […] Other therapies may be helpful if a paraneoplastic syndrome has caused significant disability: […] Physical therapy. Specific exercises may help you regain some muscle function that has been damaged. […] Speech therapy. If you are having trouble speaking or swallowing, a speech therapist can help you relearn the necessary muscle control.

• #42 Paraneoplastic syndromes of the nervous system – Humanitas.net

  https://www.humanitas.net/diseases/paraneoplastic-syndromes-of-the-nervous-system/

  Treatment for paraneoplastic syndromes typically involves treating the cancer itself, improving symptoms and physical therapy if necessary. […] Treatment of neurological paraneoplastic syndromes involves treating the cancer and improving symptoms that cause pain and discomfort. Treatment options can include: […] Other medical procedures may include: […] Other types of therapies that may be helpful if a paraneoplastic syndrome has caused significant disability include: […] Physical therapy: A rehabilitation program that uses specific exercises to help regain muscular function and coordination. […] Speech therapy: A clinical program aimed to help improve speech skills as well as oral motor skills to relearn muscle control.

• #43 Paraneoplastic Neurologic Syndromes | Oncohema Key

  https://oncohemakey.com/paraneoplastic-neurologic-syndromes/

  The paraneoplastic neurologic syndromes include an extensive group of disorders that can affect any part of the central or peripheral nervous system. […] Antibodies directly mediate some disorders such as the Lambert-Eaton myasthenic syndrome, myasthenia gravis, and neuromyotonia and likely mediate other disorders such as anti-N-methyl-d-aspartate receptor encephalitis. In these disorders the antibodies target neuronal cell surface proteins (e.g., receptors and ion channels), and immunotherapy along with tumor treatment often result in substantial neurologic improvement. […] For these syndromes the treatment approach should be aimed at the tumor, because stabilization and, less often, improvement of neurologic symptoms after tumor treatment have been reported for almost all syndromes. In a few cases, depending on the syndrome and whether the patient is in the early stages of the neurologic disease, treatment with immunosuppression may have some effect on the paraneoplastic neurologic syndrome.

• #44 Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes

  https://www.mdpi.com/2073-4468/12/3/50

  Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells. […] The present review provides an update on the pathophysiology of paraneoplastic neurologic syndromes, as well as recommendations for their diagnosis and treatment. […] The first and most important goal of treating PNSs is identifying and treating the underlying malignancy. […] In one series examining 200 patients with SCLC and anti-Hu antibodies exhibiting paraneoplastic encephalomyelitis, tumor-directed treatment, regardless of whether immunotherapy was administered to treat the encephalomyelitis directly, resulted in 4.5 × greater odds of an improvement or stabilization of PNS. […] For PNSs mediated by antibodies directed against synaptic or cell membrane proteins (i.e., the antibodies themselves are directly pathogenic), antibody-depleting and immunosuppressive therapy can be quite effective.

• #45 Paraneoplastic neurological syndromes: a practical approach to diagnosis and management | Practical Neurology

  https://pn.bmj.com/content/22/1/19

  More than 80% of treated NMDAR-antibody encephalitis can be expected to have a good outcome at 24 months, a figure likely to have increased since better recognition and more effective treatment protocols are commonplace. […] The syndromes associated with surface antibodies to mGluR1 and mGluR5, despite common associations with lymphoma, are typically immunotherapy responsive, and 50% of patients with mGluR5-autoantibodies can make a full recovery.

• #46 Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes

  https://www.mdpi.com/2073-4468/12/3/50

  First-line immunotherapy typically consists of corticosteroids, intravenous immunoglobulin (IVIG) and/or plasmapheresis. […] Unfortunately, PNSs caused by antibodies directed against intracellular antigens and mediated by T cells tend to be poorly responsive to treatment. […] For these patients, in addition to treating the primary malignancy, early and aggressive immunomodulatory and immunosuppressive treatment with corticosteroids and IVIG provide the best chance of neurologic recovery, likely because neuronal damage is not yet complete. […] More aggressive cytotoxic (e.g., cyclophosphamide, an alkylating agent that predominantly depletes T cells) or immunosuppressive (e.g., tacrolimus and cyclosporine) agents can also be trialed. […] Unfortunately, PNSs caused by antibodies directed against intracellular antigens and mediated by T cells tend to be poorly responsive to treatment.

• #47 Paraneoplastic neurological syndromes: a practical approach to diagnosis and management | Practical Neurology

  https://pn.bmj.com/content/22/1/19

  While many cases with onconeuronal antibodies are immunotherapy-resistant or only partially responsive, it is important to recognise certain syndromes in which there is stronger evidence for immune-directed treatment. […] On the other hand, there is limited evidence for a symptomatic benefit of immunotherapy in Hu-antibody neuropathy, and the main predictors of outcome among all patients with this specificity are disability/performance status, age and multifocal disease. […] Many cases of paraneoplastic cerebellar degeneration remain refractory to treatment even if the underlying malignancy is successfully addressed, a situation which is particularly observed with Yo-antibodies. […] In marked contrast, overall, the vast majority of patients with surface neuronal antibodies are immunotherapy-sensitive.

• #48 Paraneoplastic neurological syndromes: a practical approach to diagnosis and management | Practical Neurology

  https://pn.bmj.com/content/22/1/19

  While many cases with onconeuronal antibodies are immunotherapy-resistant or only partially responsive, it is important to recognise certain syndromes in which there is stronger evidence for immune-directed treatment. […] On the other hand, there is limited evidence for a symptomatic benefit of immunotherapy in Hu-antibody neuropathy, and the main predictors of outcome among all patients with this specificity are disability/performance status, age and multifocal disease. […] Many cases of paraneoplastic cerebellar degeneration remain refractory to treatment even if the underlying malignancy is successfully addressed, a situation which is particularly observed with Yo-antibodies. […] In marked contrast, overall, the vast majority of patients with surface neuronal antibodies are immunotherapy-sensitive.

• #49 Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment

  https://www.mdpi.com/2227-9059/11/5/1406

  Paraneoplastic neurological syndromes (PNS) include any symptomatic and non-metastatic neurological manifestations associated with a neoplasm. […] Clinicians should have a high index of suspicion with acute/subacute encephalopathies to achieve a prompt diagnosis and treatment. […] Standardized diagnostic criteria and disease biomarkers are fundamental to quickly recognize PNS to allow prompt treatment initiation, thus improving the long-term outcome of these conditions. […] The first step of PNS treatment is the oncological treatment (systemic or surgical) of the underlying tumor, when diagnosed, followed by the administration of immune treatments, when required. […] For example, patients with testicular germ-cell tumors and anti-Ma2 encephalitis, may benefit from radical orchiectomy followed by steroid therapy, with about 35% of cases showing good treatment response.

• #50 Paraneoplastic Neurological Syndromes: Diagnosis and Treatment Strategies | Maggie Yu MD, IFMCP

  https://drmaggieyu.com/blog/paraneoplastic-neurological-syndromes-diagnosis-and-treatment-strategies/

  PNS presents several challenges due to its autoimmune nature. The immune system mistakenly attacks healthy cells in the nervous system, leading to complex symptoms. This makes it difficult to find a one-size-fits-all treatment strategy. Each patients condition is unique, requiring personalized treatment plans. […] Personalized treatment plans are essential for effective PNS management. These plans consider individual patient needs and disease presentations. […] Managing refractory cases of PNS is particularly challenging. Some patients do not respond well to standard treatments, necessitating alternative agents or combination therapies.

• #51 Paraneoplastic Cerebellar Degeneration Treatment & Management: Approach Considerations, Medical Care, Surgical Care

  https://emedicine.medscape.com/article/1156965-treatment

  The response of the paraneoplastic neurologic syndromes to immunosuppressive agents or antitumor treatment is influenced greatly by the underlying neuropathology. […] The effect of the combination of intravenous immunoglobulins (IVIG), cyclophosphamide, and methylprednisolone on the clinical course of patients with paraneoplastic neurologic syndrome (PNS) or paraneoplastic cerebellar degeneration (PCD) and antineuronal antibodies is poor. This may be partly due to T-cell involvement in the cerebellar damage. However, due to the severe disability of the condition and the presence of some positive responders found in the literature, it is reasonable to trial a course of immunotherapy in an attempt to reduce morbidity. […] Some reports indicate partial or complete remission of cerebellar symptoms after treating the primary neoplasm. This has been observed only in small-cell carcinomas and is not reported in gynecologic malignancies.

• #52 Paraneoplastic Neurological Disorders | PM&R KnowledgeNow

  https://now.aapmr.org/neuromuscular-manifestations-of-neoplasms-and-paraneoplastic-syndromes/

  Coordination between the physiatrist, therapist, oncologist, and neurologist are paramount. Particular attention should be made when coordinating therapies and any concurrent cancer treatment to ensure there are no scheduling conflicts and to ensure that the patient can actively participate in therapy. […] Frequent education of the patient and family helps patients make informed decisions regarding their disease course. The patient should be aware of the cancer prognosis and what symptoms reflect worsening course of the cancer versus what symptoms are associated entirely with nerve damage caused by the PNS. Furthermore, the patient and family should be counseled regarding appropriate treatment options for the underlying malignancy including surgery, chemotherapy and radiotherapy, when appropriate.

• #53

  https://www.ama.ba/index.php/ama/article/view/574

  Paraneoplastic syndromes are related to the presence of a malignancy and are not secondary to treatment. […] Paradoxally, both a malignancy and its therapeutic approach may cause a series of PNSs. […] Immunosuppressants, intravenous immunoglobulins, plasma exchange, rituximab, cyclophosphamide, azathioprine, and tocilizumab could be considered as treatment agents. […] Most patients demonstrate poor PNS treatment results with common relapse. […] A multidisciplinary team is needed for potentially earlier diagnosis and PNS improvement, better prognosis, and increased overall survival and quality of life.

• #54 Paraneoplastic Neurological Disorders | PM&R KnowledgeNow

  https://now.aapmr.org/neuromuscular-manifestations-of-neoplasms-and-paraneoplastic-syndromes/

  Coordination between the physiatrist, therapist, oncologist, and neurologist are paramount. Particular attention should be made when coordinating therapies and any concurrent cancer treatment to ensure there are no scheduling conflicts and to ensure that the patient can actively participate in therapy. […] Frequent education of the patient and family helps patients make informed decisions regarding their disease course. The patient should be aware of the cancer prognosis and what symptoms reflect worsening course of the cancer versus what symptoms are associated entirely with nerve damage caused by the PNS. Furthermore, the patient and family should be counseled regarding appropriate treatment options for the underlying malignancy including surgery, chemotherapy and radiotherapy, when appropriate.

• #55 Paraneoplastic syndromes of the nervous system

  https://johnsonmemorial.org/jmh-health-information-library-disease/con-20251949

  Intravenous immunoglobulin (IVIg). Immunoglobulin contains healthy antibodies from blood donors. High doses of immunoglobulin speed up the destruction of the damaging antibodies in your blood. […] If you have a paraneoplastic neurologic syndrome, it’s generally recommended that you don’t use certain cancer medicines called immune checkpoint inhibitors. These treatments activate the immune system to fight cancer. While this can help destroy the cancer, it also can lead to worsening of the immune attack on the nervous system. […] Other therapies may be helpful if a paraneoplastic syndrome has caused disability: Physical therapy. Specific exercises may help you regain some lost muscle function. […] Speech therapy. A speech therapist can help you relearn the necessary muscle control if you are having trouble speaking or swallowing.

• #56 Paraneoplastic syndromes of the nervous system – Hancock Health

  https://www.hancockhealth.org/es/mayo-health-library/paraneoplastic-syndromes-of-the-nervous-system/

  Other treatments that may improve symptoms include: […] If you have a paraneoplastic neurologic syndrome, it’s generally recommended that you don’t use certain cancer medicines called immune checkpoint inhibitors. […] Other therapies may be helpful if a paraneoplastic syndrome has caused disability: […] Many people with cancer benefit from education and resources designed to improve coping skills. […] If you have questions or would like guidance, talk with a member of your healthcare team. The more you know about your condition, the better you’re able to participate in decisions about your care.

• #57 Paraneoplastic Neurological Disorders | PM&R KnowledgeNow

  https://now.aapmr.org/neuromuscular-manifestations-of-neoplasms-and-paraneoplastic-syndromes/

  Improvement from immunotherapy treatment can be measured by any increase in Rankin score or a 10-point increase in Barthel functional index. Functional Independence Measure (FIM) is a useful measurement in the setting of acute inpatient rehabilitation. […] PNS is difficult to diagnose but early diagnosis and initiation of treatment is critical to prevent permanent neurological deficits. Symptoms of PNS may include ataxia, encephalitis, peripheral neuropathy, memory problems, seizures, sensory motor neuropathies, anorexia, rapid weight loss and fatigue. PNS may precede the diagnosis of the underlying malignancy. The discovery and detection of antibodies continues to expand and can help expedite direct care. Antibodies to neuronal surface antigens, synaptic receptors, intracellular antigens, neuromuscular junction antigens, voltage gated potassium channels, glutamate receptors, GABA and glycine receptors have been found, and some of these antibodies are excellent predictors of favorable response to immunotherapy.

• #58 Urging Awareness of Paraneoplastic Syndromes – NYU Langone Health Physician Focus

  https://physicianfocus.nyulangone.org/urging-awareness-of-paraneoplastic-syndromes/

  If cancer is not detected upon initial presentation, we keep the patient on maintenance immunotherapy for about two years. This keeps the patient stable while we continue searching for the source. […] Healing from neurological paraneoplastic syndromes can take months to years. Patience and early rehabilitation are fundamental.

• #59 Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes

  https://www.mdpi.com/2073-4468/12/3/50

  Prognosis can vary depending on the specific PNS and the underlying pathophysiology. […] As mentioned previously, some disorders, such as LEMS and myasthenia gravis, respond well to immunosuppressive therapy and to treatment of the underlying tumor. […] Conversely, disorders such as paraneoplastic cerebellar degeneration are typically associated with neuronal damage. […] Immune suppression remains the mainstay of PNS treatment, but more prospective studies are needed to evaluate the efficacy of various immunotherapeutic approaches.

• #60 Paraneoplastic Syndromes and Lymphoma | MyLymphomaTeam

  https://www.mylymphomateam.com/resources/paraneoplastic-syndromes-and-lymphoma

  People may notice the symptoms of a paraneoplastic syndrome before they notice any symptoms from underlying cancer. […] Prompt and effective diagnosis and treatment of paraneoplastic syndromes is important because these syndromes can affect outcomes related to lymphoma. […] If someone has paraneoplastic syndromes, the syndromes can be treated in many different ways, such as treating underlying cancer. […] As there are also many types of paraneoplastic syndromes, the treatment of paraneoplastic symptoms varies depending on which type it is and what part of the body is being attacked. […] Because these syndromes are related to inflammation and the autoimmune system, treatment options can include: Corticosteroids Reduce inflammation, Intravenous immunoglobulins Boost healthy antibodies, Immunosuppressants Manage the immune systems response, Plasmapheresis Reduces the amount of antibodies in the blood, Speech and physical therapy Helps people speak and move better.

• #61 Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes

  https://www.mdpi.com/2073-4468/12/3/50

  Prognosis can vary depending on the specific PNS and the underlying pathophysiology. […] As mentioned previously, some disorders, such as LEMS and myasthenia gravis, respond well to immunosuppressive therapy and to treatment of the underlying tumor. […] Conversely, disorders such as paraneoplastic cerebellar degeneration are typically associated with neuronal damage. […] Immune suppression remains the mainstay of PNS treatment, but more prospective studies are needed to evaluate the efficacy of various immunotherapeutic approaches.

• #62 What Is Paraneoplastic Syndrome? Understanding This Rare Condition

  https://drchandrilchugh.com/paraneoplastic-syndromes/what-is-paraneoplastic-syndrome-understanding-this-rare-condition/

  Therapies that help you cope, like speech or physical therapy, can be important. They focus on the nervous system effects of paraneoplastic syndromes. They aim to help you live better, even with ongoing challenges. Its vital to work closely with your healthcare team to create the best plan for you. […] The prognosis varies with the cancers stage at diagnosis. Early detection and cancer treatment with an autoimmune response focus could prevent further nerve damage. This might also improve symptoms and life quality.

• #63 Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes

  https://www.mdpi.com/2073-4468/12/3/50

  Prognosis can vary depending on the specific PNS and the underlying pathophysiology. […] As mentioned previously, some disorders, such as LEMS and myasthenia gravis, respond well to immunosuppressive therapy and to treatment of the underlying tumor. […] Conversely, disorders such as paraneoplastic cerebellar degeneration are typically associated with neuronal damage. […] Immune suppression remains the mainstay of PNS treatment, but more prospective studies are needed to evaluate the efficacy of various immunotherapeutic approaches.

• #64 Paraneoplastic Neurological Syndromes (PNS) research group | University of Bergen

  https://www.uib.no/en/rg/pns

  Paraneoplastic syndromes of the nervous system are rare immune-mediated disorders that manifest in individuals with cancer. […] Our primary objective is to pioneer a neuroprotective therapy by delving into the molecular mechanisms that trigger neurodegeneration. The current therapeutic approach involves tumor removal to prevent further neuronal damage. However, PCD symptoms often precede cancer diagnosis, and tumors are frequently too small to be localized at that stage, complicating this treatment. Unfortunately, there is currently no other effective treatment available to counteract the induced neurodegeneration. […] Through these approaches, we aim to gain valuable insights into the intricate processes underlying neurodegeneration, ultimately paving the way for effective and targeted neuroprotective interventions.

Zobacz więcej